Bank Of New York Mellon Corp Fate Therapeutics Inc Transaction History

Bank Of New York Mellon Corp

$541 Trillion
Q4 2024

22 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 09, 2023	BUY	$4.24 - $11.12 $1.51 Million - $3.95 Million	355,192 New	355,192 $2.02 Billion
Q4 2022 Feb 14, 2023	BUY	$9.86 - $23.83 $3.58 Million - $8.65 Million	363,074 New	363,074 $3.66 Million
Q3 2022 Nov 14, 2022	BUY	$21.04 - $36.06 $836,108 - $1.43 Million	39,739 Added 11.34%	390,269 $8.75 Million
Q2 2022 Aug 15, 2022	SELL	$17.78 - $42.39 $78,569 - $187,321	-4,419 Reduced 1.24%	350,530 $8.69 Million
Q1 2022 May 11, 2022	SELL	$29.67 - $60.28 $102,242 - $207,724	-3,446 Reduced 0.96%	354,949 $13.8 Million
Q4 2021 Feb 11, 2022	BUY	$47.84 - $64.34 $721,666 - $970,568	15,085 Added 4.39%	358,395 $21 Million
Q3 2021 Nov 12, 2021	BUY	$59.27 - $95.73 $938,955 - $1.52 Million	15,842 Added 4.84%	343,310 $20.3 Million
Q2 2021 Aug 11, 2021	BUY	$67.25 - $92.52 $1.56 Million - $2.14 Million	23,128 Added 7.6%	327,468 $28.4 Million
Q1 2021 May 13, 2021	SELL	$72.16 - $117.4 $785,317 - $1.28 Million	-10,883 Reduced 3.45%	304,340 $25.1 Million
Q4 2020 Feb 09, 2021	SELL	$38.09 - $100.95 $39,461 - $104,584	-1,036 Reduced 0.33%	315,223 $28.7 Million
Q3 2020 Nov 12, 2020	BUY	$30.41 - $40.5 $996,657 - $1.33 Million	32,774 Added 11.56%	316,259 $12.6 Million
Q2 2020 Aug 12, 2020	SELL	$20.21 - $35.23 $323 - $563	-16 Reduced 0.01%	283,485 $9.73 Million
Q1 2020 May 06, 2020	BUY	$17.28 - $31.88 $777,461 - $1.43 Million	44,992 Added 18.86%	283,501 $6.3 Million
Q4 2019 Feb 14, 2020	BUY	$13.39 - $20.73 $267,706 - $414,454	19,993 Added 9.15%	238,509 $4.67 Million
Q3 2019 Nov 07, 2019	SELL	$15.47 - $22.5 $203,260 - $295,627	-13,139 Reduced 5.67%	218,516 $3.39 Million
Q2 2019 Aug 12, 2019	SELL	$15.61 - $20.44 $300,211 - $393,102	-19,232 Reduced 7.67%	231,655 $4.7 Million
Q1 2019 May 14, 2019	BUY	$13.15 - $18.71 $70,681 - $100,566	5,375 Added 2.19%	250,887 $4.41 Million
Q4 2018 Feb 11, 2019	SELL	$11.48 - $16.98 $244,099 - $361,045	-21,263 Reduced 7.97%	245,512 $3.15 Million
Q3 2018 Nov 09, 2018	SELL	$8.75 - $16.29 $207,847 - $386,952	-23,754 Reduced 8.18%	266,775 $0
Q2 2018 Aug 06, 2018	BUY	$9.16 - $13.48 $126,765 - $186,549	13,839 Added 5.0%	290,529 $3.29 Million
Q1 2018 May 15, 2018	BUY	$6.3 - $13.77 $782,466 - $1.71 Million	124,201 Added 81.45%	276,690 $2.7 Million
Q4 2017 Feb 09, 2018	BUY	$3.94 - $6.64 $600,806 - $1.01 Million	152,489	152,489 $931,000

Others Institutions Holding FATE

# of Institutions

167

Shares Held

101M

Call Options Held

41.3K

Put Options Held

15.9K

Redmile Group, LLC San Francisco, CA

12.9M
Shares

$11.8 Million
1.66% of portfolio
Vanguard Group Inc Valley Forge, PA

10.3M
Shares

$9.51 Million
0.0% of portfolio
Black Rock Inc. New York, NY

10.1M
Shares

$9.31 Million
0.0% of portfolio
Bellevue Group Ag Kuesnacht, V8

4.84M
Shares

$4.45 Million
0.16% of portfolio
Ken Griffin Citadel Advisors LLC | Chicago, Il

4.38M
Shares

$4.03 Million
0.0% of portfolio

View Full List

About FATE THERAPEUTICS INC

Ticker FATE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 97,000,304
Market Cap $89.2M
Description
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development include FT516 for the treatment of acute myeloid leukemia (AML) B-cell lymphoma, and advanced solid tumor; FT596 to treat B-cell...

More about FATE

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Bank Of New York Mellon Corp, based on Form 13F filings with the SEC.

News

Stay updated on Bank Of New York Mellon Corp with notifications on news.

Account